Literature DB >> 2477343

Endothelial cell-stimulating angiogenesis factor in vitreous from extraretinal neovascularizations.

C M Taylor1, R D Kissun, A M Schor, D McLeod, A Garner, J B Weiss.   

Abstract

The presence of endothelial cell-stimulating angiogenic factor (ESAF) in diseased human vitreous humour has been established. The molecular mass and chromatographic behavior of this material and its property of activating procollagenase indicate it to be identical to the ESAF isolated from other sources. The biological activity of ESAF from human vitreous was demonstrated by its ability to induce positive responses in the rabbit corneal pocket, and in the chick chorioallantoic membrane and yolk sac membrane tests.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2477343

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  4 in total

1.  Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management.

Authors:  M Boulton; Z Gregor; D McLeod; D Charteris; J Jarvis-Evans; P Moriarty; A Khaliq; D Foreman; D Allamby; B Bardsley
Journal:  Br J Ophthalmol       Date:  1997-03       Impact factor: 4.638

2.  Biological activities of vitreous gel, retrohyaloid fluid and subretinal fluid from diabetic and non-diabetic eyes.

Authors:  M Boulton; P Moriarty; Z J Gregor
Journal:  Br J Ophthalmol       Date:  1992-02       Impact factor: 4.638

Review 3.  A chronic grey matter penumbra, lateral microvascular intussusception and venous peduncular avulsion underlie diabetic vitreous haemorrhage.

Authors:  David McLeod
Journal:  Br J Ophthalmol       Date:  2007-05       Impact factor: 4.638

Review 4.  Angiogenesis-Inflammation Cross Talk in Diabetic Retinopathy: Novel Insights From the Chick Embryo Chorioallantoic Membrane/Human Vitreous Platform.

Authors:  Sara Rezzola; Alessandra Loda; Michela Corsini; Francesco Semeraro; Tiziana Annese; Marco Presta; Domenico Ribatti
Journal:  Front Immunol       Date:  2020-09-29       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.